from seed to market.
The Trendlines Group invests in innovations in agrifood technologies and medtech, leveraging our experience, network, and resources to go from seed to market.
Vensica has developed minimally invasive solutions in urology, unlocking the unique properties of therapeutic ultrasound to deliver neurotoxins.
Vensica’s journey from our establishment in 2014, through to our strategic partnership with Merz and the latest investment round, took many twists and turns. Trendlines was there for us at each stage.
Avner Geva, CEO Vensica Therapeutics
Strategic license and collaboration agreement with Merz Therapeutics
Full development of a needle-less delivery system utilizing the power of therapeutic ultrasound
$19 million investment round led by Israeli VC IBF
Phytolon revolutionizes the way food colors are produced, bringing natural colors to the next level in terms of ...
The investments of DSM Venturing, Cibus Fund, and Ginkgo Bioworks open the door for broad penetration of our products in the global food industry. We are excited to have new investors who share our vision to create healthy, efficient, and sustainable food systems via biotechnology.
Halim Jubran PhD, Co-founder and CEO of Phytolon
Closed $14.5 million Series A funding round
Signed collaboration with Ginkgo Bioworks
Selected as one of top 30 global start-ups at SLINGSHOT 2019, Singapore, November 2019
15 November 2022
Collaborative study by NeuroQuest and AIBL shows specific biomarkers for Alzheimer’s could lead to blood-based screening tool
7 November 2022
Trendlines invests in Celleste Bio to make our chocolate supply sustainable
Co-investors include Mondelēz International, Barrel Ventures and Regba Group
31 August 2022
Trendlines takes Bronze Award for Best Managed Board
We are honored to share that Trendlines was awarded the Bronze Award...
Misgav Business Park, 17 T’chelet Street M.P. Misgav, 2017400
Blk 77, Ayer Rajah Crescent, #02-21/26 Singapore, 139954